J&J (NYSE:JNJ) declined in the second quarter after delivering strong returns in 2016 and 2017. It faces generic challenges to some of its major pharmaceuticals, but we believe J&J is well diversified and positioned to provide solid growth over time.
From Yacktman Fund (Trades, Portfolio)'s 2nd quarter 2018 shareholder letter.